Monday, January 10, 2000
While many start-up biotech companies employ either a single platform technology, or multiple disciplines that are not necessarily related, Intercell GmbH has opted for a middle ground. The company applies its Cistem screening technology to identify vaccine candidate molecules and then uses these molecules in its Transvax platform to generate vaccines.
With these two complementary technologies, Intercell hopes to develop vaccines in the areas of cancer and infectious diseases. Intercell is the first company to spin out of the Vienna Biocenter, a basic research institute, which still serves as Intercell's headquarters and research facilities.